Isoaminile

From WikiMD's WELLNESSPEDIA

Isoaminile


Isoaminile is a cough suppressant and analgesic that was previously used in over-the-counter (OTC) medications. It is a member of the ethylmorphine class of drugs, which also includes codeine and dihydrocodeine. Isoaminile was withdrawn from the market due to concerns about its potential for abuse and addiction.

History[edit]

Isoaminile was first synthesized in the 1950s as a potential alternative to codeine. It was marketed under the brand name Pertofrane by the French pharmaceutical company Rhône-Poulenc. However, it was later withdrawn from the market due to concerns about its potential for abuse and addiction.

Pharmacology[edit]

Isoaminile acts as a mu-opioid receptor agonist, similar to other drugs in the ethylmorphine class. This means it binds to and activates the mu-opioid receptors in the brain, which are responsible for mediating the effects of opioids. This results in a reduction in cough reflex and pain sensation.

Side Effects[edit]

The side effects of Isoaminile are similar to those of other opioids and can include drowsiness, nausea, constipation, and respiratory depression. In addition, long-term use can lead to physical dependence and withdrawal symptoms upon cessation.

Legal Status[edit]

Isoaminile is currently a Schedule II controlled substance in the United States, meaning it has a high potential for abuse and its use is severely restricted. It is also controlled under similar laws in many other countries.

See Also[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.